Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for Recothrom, and a broad label for its use to control bleeding during surgery. Recothrom is the first recombinant thrombin and will compete with a bovine thrombin product sold by Bristol, Tennessee–based King Pharmaceuticals, the market leader, and a human plasma-derived thrombin, Evithrom, from Omrix Pharmaceuticals in New York. (Evithrom was approved in 2007 and is being sold by Johnson & Johnson, of New Brunswick, New Jersey.) Zymogenetics decided to enter the thrombin market after watching King increase pricing and grow its Thrombin-JMI franchise to well above $200 million annually, even with a 'black box' warning for potential immunogenicity. It has reason to think its product could compete because “at the end of the day, there isn't a single example where a recombinant protein fails to take the market over something from plasma or tissue,” notes Zymogenetics CEO Bruce Carter. Nonetheless, Wall Street's reaction to the approval was swift and negative: Zymogenetics' stock fell $2 on approval. “We are mystified that there isn't more enthusiasm in the investor community,” says Carter. Analyst skepticism is twofold: King has apparently begun discounting the price of Thrombin-JMI to try to keep its market share, and Wall Street fears that Johnson & Johnson hasn't made its best moves yet in promoting Evithrom. All three products appear effective. “Thrombin stops bleeding, whether it's in a cow or a person,” notes Piper Jaffray analyst Edward Tenthoff, in New York, and “there isn't a meaningful difference in time to hemostasis” among the three products. With respect to the benefits of a recombinant product, he adds that “in a litigious environment, some will say safety for an increased price is worth it.” Tenthoff says Recothrom will eventually succeed and that the market for thrombin will grow: according to Zymogenetics, there are currently 1.3 million US thrombin procedures, 3.5 million topical hemostat procedures and over 11 million potential procedures annually where thrombin may be used. MR
Rights and permissions
About this article
Cite this article
Ratner, M. Recombinant thrombin approved. Nat Biotechnol 26, 250 (2008). https://doi.org/10.1038/nbt0308-250
Issue Date:
DOI: https://doi.org/10.1038/nbt0308-250